Voyager Therapeutics reports Q4 results
- Co reports Q4 EPS of ($0.40) vs ($0.73) Capital IQ Consensus; revs +162.5% y/y to $6.3 mln vs $4.5 mln Capital IQ Consensus
- Recent AbbVie (ABBV) collaboration successfully leveraged Voyager's gene therapy platform and expertise and strengthened the balance sheet to extend cash runway into early 2020.
- During mid-2018, dose the first patient in the planned Phase 2-3 pivotal program for advanced Parkinson's disease. Neurosurgical and neurology clinical trial sites have been identified and are being activated through institutional review board processes, after which, patient referral, screening and dosing can proceed.
No comments:
Post a Comment